Epigenetic adaptations and vulnerabilities in ovarian cancer drug-tolerant persister cells
NAR Cancer · 2026
DOI: 10.1093/narcan/zcag030 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift NAR Cancer, 2026. Verfasst von Mihai G Dumbrava und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Investigative Pathobiology, Department of Lab Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, United States. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Epigenesis, Genetic, Drug Resistance, Neoplasm, Neoplasm Recurrence, Local. Die Arbeit nennt 116 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIGMS NIH HHS, Mayo Clinic.
Abstract (Originalsprache)
High-grade serous ovarian carcinoma (HGSOC) recurs in most patients despite initial responses to chemotherapy and poly(ADP-ribose) polymerase inhibition. A leading explanation for the high rates of recurrence is the presence of minimal residual disease (MRD) comprised of drug-tolerant persister (DTP) cells that survive therapy through reversible epigenetic reprogramming. DTPs have various adaptations that enable them to tolerate therapy and eventually develop into resistant clones, including quiescence, metabolic and hypoxic stress responses, epithelial-mesenchymal plasticity, and immune evasion. Here, we discuss evidence from ovarian cancer of epigenetic mechanisms that coordinate DTP phenotypes, including DNA methylation, histone post-translational modifications, enhancer rewiring, and transcription factor gene-regulatory networks. Based on therapeutic vulnerabilities identified from increased resolution of DTPs, we highlight epigenetic therapies that are currently in clinical trials aimed at depleting MRD to delay or prevent relapse in HGSOC. Finally, we outline emerging technologies that have the potential to detect and monitor persister states in patients, including single-cell transcriptomic and epigenomic profiling, long-read sequencing, and spatial mapping of tumor biopsies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Investigative Pathobiology, Department of Lab Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, United States.
- Mayo Medical Scientist Training Program, Mayo Clinic, Rochester, MN 55905, United States.
- Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic, Rochester, MN 55905, United States.
- Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN 55905, United States.
ORCID-Profile: Alexandre Gaspar-Maia
Förderung
- NCI NIH HHS
- NIGMS NIH HHS
- Mayo Clinic
- Department of Defense Ovarian Cancer
- Ovarian Cancer Academy
- Department of Defense Ovarian Cancer Research Program
- Canadian Institutes of Health Research
- Foundation for Women Wellness
Zitieren
APA
Dumbrava, M. G., Hamernick, S. J., Harrington, S. P., & Gaspar-Maia, A. (2026). Epigenetic adaptations and vulnerabilities in ovarian cancer drug-tolerant persister cells. NAR Cancer. https://doi.org/10.1093/narcan/zcag030
Vancouver
Dumbrava MG, Hamernick SJ, Harrington SP, Gaspar-Maia A. Epigenetic adaptations and vulnerabilities in ovarian cancer drug-tolerant persister cells. NAR Cancer. 2026. doi:10.1093/narcan/zcag030
BibTeX
@article{Dumbrava2026,
author = {Dumbrava, Mihai G and Hamernick, Sierra J and Harrington, Shariska P and Gaspar-Maia, Alexandre},
title = {Epigenetic adaptations and vulnerabilities in ovarian cancer drug-tolerant persister cells},
journal = {NAR Cancer},
year = {2026},
doi = {10.1093/narcan/zcag030}
}
EUVIMED